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Asthma is a common and heterogeneous inflam-
matory disorder of the airways (Anderson, 2008). 
Studies of patients and animal models suggest 
that TH2 memory cells that reside in the lung 
during disease remission contribute to the persis-
tence and progression of asthma (Robinson et al., 
1992; Epstein, 2006). In the allergic form of 
asthma, repetitive exposure to allergens activates 
allergen-specific resident TH2 memory cells to 
trigger production of chemokines and proinflam-
matory cytokines and recruitment of other in-
flammatory leukocytes (Cohn et al., 2004). 
In addition to allergens, environmental factors 
or infectious pathogens often trigger epithelial 
stress and altered innate immunity that induce 
different types of inflammation, thereby result-
ing in the heterogeneous forms of asthma 
(Simpson et al., 2006; Holgate, 2007).
Since the identification of IL-17 from acti-
vated T cell clones (Yao et al., 1995a), five ad-
ditional family members have been discovered 
and designated as IL-17A–F (Li et al., 2000; Lee 
et al., 2001; Starnes et al., 2001). The discovery 
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The inflammatory cytokine interleukin (IL)-17 is involved in the pathogenesis of allergic 
diseases. However, the identity and functions of IL-17–producing T cells during the patho-
genesis of allergic diseases remain unclear. Here, we report a novel subset of TH2 memory/
effector cells that coexpress the transcription factors GATA3 and RORt and coproduce 
TH17 and TH2 cytokines. Classical TH2 memory/effector cells had the potential to produce 
IL-17 after stimulation with proinflammatory cytokines IL-1, IL-6, and IL-21. The number 
of IL-17-TH2 cells was significantly increased in blood of patients with atopic asthma. In a 
mouse model of allergic lung diseases, IL-17–producing CD4+ TH2 cells were induced in the 
inflamed lung and persisted as the dominant IL-17–producing T cell population during the 
chronic stage of asthma. Treating cultured bronchial epithelial cells with IL-17 plus TH2 
cytokines induced strong up-regulation of chemokine eotaxin-3, Il8, Mip1b, and Groa gene 
expression. Compared with classical TH17 and TH2 cells, antigen-specific IL-17–producing 
TH2 cells induced a profound influx of heterogeneous inflammatory leukocytes and exacer-
bated asthma. Our findings highlight the plasticity of TH2 memory cells and suggest that 
IL-17–producing TH2 cells may represent the key pathogenic TH2 cells promoting the exac-
erbation of allergic asthma.
© 2010 Wang et al. This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution– 
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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RESULTS
A novel subset of human TH2 memory/effector cells 
produces IL-17
CCR6 was a useful marker for the identification of IL-17– 
producing cells in the human memory T cell pool (Acosta- 
Rodriguez et al., 2007). CRTH2 were reported to be the most 
reliable marker to identify human CD4+ TH2 memory cells 
(Cosmi et al., 2000; Wang et al., 2006). The characterization of 
human CRTH2+CD4+ TH2 cells led us to identify a distinctive 
subset of TH2 cells expressing a high level of CCR6 (Fig. 1 a). 
To investigate whether the CCR6+ subset of CRTH2+CD4+ 
TH2 cells also display features of TH17 cells, freshly purified 
CCR6+ and CCR6 subsets of CRTH2+CD4+ TH2 cells 
from the peripheral blood were stimulated with anti-CD3/
CD28 mAbs for 24 h, and their secreted cytokines were exam-
ined using ELISA. Both subsets of CRTH2+CD4+ TH2 cells 
produced classical TH2 cytokines IL-4, IL-5, and IL-13, but 
not IFN-; notably, only the CCR6+ subset of TH2 cells could 
produce TH17 cytokines IL-17 and IL-22 (Fig. 1 b). Both sub-
sets exhibit a memory T cell phenotype featuring the expres-
sion of CD45RO, CCR7, CD27, and CD62L, as well as 
CCR4 and CXCR4, the chemokine receptors expressed by 
TH2 cells (Fig. 1 c and not depicted). Notably, both TH2 cell 
subsets express low levels of surface IL-1RI, but do not express 
IL-23R; additionally, very few of them express CD161 (<2%), 
which is the marker of human TH17 precursors (Fig. 1 c; 
Acosta-Rodriguez et al., 2007; Annunziato et al., 2007; Cosmi 
et al., 2008). These findings reveal a novel subset of human 
TH2 cells that are capable of producing inflammatory IL-17 
cytokine and expresses chemokine receptors for homing to the 
skin and other mucosal tissues.
Because RORt expression is essential for the generation of 
the classical IL-17–producing CD4+ T cells (Ivanov et al., 2006), 
we analyzed the expression of RORt transcript in the follow-
ing cell populations: CCR6+CRTH2+ IL-17–producing 
TH2 cells, classical CCR6CRTH2+ TH2 cells, CCR6+ 
CRTH2 TH17 cells (Acosta-Rodriguez et al., 2007), in vitro-
generated TH1 cells, and CD4+CD45RO naive T cells. Both 
TH17 and IL-17–producing TH2 cells were found to express a 
significant level of RORt transcript; in contrast, classical TH2, 
TH1, or naive T cells did not (Fig. 1 d). Although both IL-17–
producing TH2 and classical TH2 cells expressed the master tran-
scription factor for TH2 development, GATA3, these TH2 cell 
subsets did not express T-bet, the transcription factor for TH1 
development (Fig. 1 d). These data demonstrate that 
CCR6+CRTH2+ IL-17–producing TH2 cells can concur-
rently express RORt and GATA3, which are the master tran-
scription factors for TH17 cells and TH2 cells, respectively.
To further test whether IL-17 and IL-4 are concomitantly 
produced at the single-cell level, IL-17–producing TH2 cells, 
classical TH2 cells, and TH17 cells were isolated and maintained 
with homeostatic cytokines (IL-7 and IL-15) for 3 d before intra-
cellular cytokine analyses. We found that a significant fraction of 
IL-17–producing TH2 cells produced cytokines IL-4 and IL-17 
concurrently, whereas classical TH2 cells produced mostly IL-4, 
but little IL-17 (Fig. 2 a). Conversely, the classical TH17 cells 
of the IL-17 cytokine family and the analysis of IL-23– 
mediated immune pathogenesis have led to the delineation 
of a new CD4+ T helper cell population termed TH17 
(Yao et al., 1995b; Aarvak et al., 1999; Cua et al., 2003; 
Murphy et al., 2003; Harrington et al., 2005; Park et al., 
2005a). The retinoic acid–related orphan receptor (RORt) is 
the master transcription factor for the development of TH17 
cell lineage, which can be characterized by their secretion of 
the proinflammatory cytokines IL-17, IL-17F, and IL-22 
(Ivanov et al., 2006). Studies in vitro have observed that in 
the absence of IL-4 and IFN-, TGF-, and IL-21 or IL-23 
are important for the induction of RORt expression, and 
that the proinflammatory cytokines IL-1 or IL-6 can trigger 
IL-17 cytokine production (Mangan et al., 2006; Veldhoen 
et al., 2006; Wilson et al., 2007; Manel et al., 2008; Volpe 
et al., 2008; Yang et al., 2008). During Th cell differentiation, 
transcription factors T-bet and GATA-3 are mutually inhibi-
tory for TH2 and TH1 differentiation, respectively. Although 
T-bet is a negative regulator for TH17 differentiation, en-
forced expression of GATA-3 does not restrain the differ-
entiation of IL-17–producing T cells, despite the loss of 
TH17-mediated pathology (van Hamburg et al., 2008). Addi-
tionally, an indispensible transcription factor for TH2 differ-
entiation, IFN regulatory factor 4 (IRF4), is also required for 
TH17 cell development, suggesting that plasticity between the 
development and maintenance of TH2 and TH17 cells may 
exist (Brüstle et al., 2007).
The discovery of IL-17–producing T cells has added an 
additional layer of complexity to the regulation of allergic 
inflammation. In asthmatic patients, IL-17 expression is in-
creased in the lungs, sputum, bronchoalveolar lavage (BAL) 
fluids, or sera, and the severity of airway hypersensitivity in 
patients correlates with IL-17 expression level (Molet et al., 
2001; Chakir et al., 2003). IL-17 and IL-17F can provoke 
neutrophil infiltration in mouse models of asthma in an a 
ntigen-specific fashion (Hellings et al., 2003), probably by 
inducing lung structural cells to secrete proinflammatory 
cytokines and chemokines such as TNF, IL-1, G-CSF, and 
IL-6 and CXCL1/Gro-, CXCL2, and CXCL8/IL-8, re-
spectively (Jovanovic et al., 1998; Laan et al., 1999; Ye et al., 
2001; Jones and Chan, 2002). Importantly, IL-17R–deficient 
mice exhibit both reduced neutrophil and eosinophil re-
cruitments (Ye et al., 2001), whereas IL-17A/ mice 
exhibited reduced TH2 responses to antigen sensitization 
(Nakae et al., 2002). Although these studies demonstrate the 
importance of IL-17–producing cells in driving the exacer-
bation of allergic inflammation, the identity and character-
istics of these cells during type-2 dominant immune response 
remain unclear. Herein, we demonstrate that a subset of TH2 
cells in both mice and humans is capable of producing large 
amounts of the proinflammatory cytokines IL-17 and IL-22, 
in addition to classical TH2 cytokines. We suggest that IL-17– 
producing CD4+ TH2 cells may be a unique subset of lung 
resident TH2 memory/effector cells with additional inflam-
matory properties and contribute to the exacerbation of 
chronic allergic asthma.
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classical CCR6CRTH2+ TH2 cells were cultured with homeo-
static cytokines (IL-7 and IL-15) plus anti–IL-4 and anti–IFN- 
mAbs in the absence or presence of select TH17-polarizing cyto-
kines for 6 d. As shown in Fig. 3 (a and b), we found that the 
TH17 polarizing cytokine IL-1, IL-6, or IL-21, but not IL-23, 
is capable of inducing the classical TH2 cells to produce signifi-
cant amounts of IL-17 as determined by ELISA and intracellular 
cytokine analyses. Notably, the treatment combination of 
IL-1, IL-6, and IL-21 together is most effective at inducing the 
classical TH2 cells to produce IL-17 and IL-22 cytokines 
(Fig. 3, a and b), possibly via up-regulation of the expression of 
TH17-associated transcription factors IRF4 and RORt, as well 
as CCR6 transcripts (Fig. 3 c). Collectively, these results suggest 
that committed TH2 memory/effector cells possess the plasticity 
to become IL-17–producing cells after stimulation with proin-
flammatory cytokines.
IL-17 and TH2 cytokines synergistically induce  
chemokine production
Severe asthma is often associated with elevated IL-17 expres-
sion and intense infiltration of neutrophils and eosinophils in 
produced mostly IL-17, but little IL-4 (Fig. 2 a). To examine 
whether GATA3 and RORt can be coexpressed at single-cell 
level, the three aforementioned T helper cell subsets were acti-
vated by anti-CD3 mAb before immunofluorescence analyses for 
expression of GATA3 and RORt. Notably, IL-17–producing 
TH2 cells were found to coexpress GATA3 and RORt in the 
nucleus (Fig. 2, b–e). Corresponding to their cytokine produc-
tion pattern, classical TH2 cells expressed only GATA3 and 
not RORt (Fig. 2 f), whereas classical TH17 cells expressed 
only RORt and not GATA3 in their nucleus (Fig. 2 g). 
These results demonstrate that IL-17–producing TH2 cells ex-
press both GATA3 and RORt transcription factors.
Proinflammatory cytokines induce classical TH2 memory 
cells to produce IL-17
Several studies demonstrated that TH1-polarizing signals could 
reprogram committed TH2 memory/effector cells to produce 
IFN-, suggesting the existence of plasticity within committed 
TH2 cells (Brugnolo et al., 2003; Filì et al., 2006; Hegazy et al., 
2010). To test whether classical TH2 cells have the potential to pro-
duce IL-17 cytokine under TH17-polarizing signals, purified 
Figure 1. Phenotypic and functional characteristics of CRTH2+CD4+ TH2 cell subsets. (a) Enriched human CRTH2hiCD4+ T cells could be divided 
into two subsets based on their surface expression of CCR6. Purified resting CCR6+ and CCR6 of CRTH2+CD4+ TH2 cells were stimulated with anti-CD3/
CD28 mAbs for the measurements of cytokines in the culture supernatants by ELISA (b) or analyzed for the expression of other surface markers (c). Filled 
histograms represent the staining of indicated cell subset with markers shown below the histogram; open histograms represent the isotype. (d) cDNA 
templates made from the indicated T cell subsets were prepared as described in the Materials and methods. Expression levels of indicated genes that are 
involved in T cell differentiation were measured by real-time PCR as described in methods. Fold differences in gene expression level between cell types 
marked in the left panel are indicated in horizontal axis. The results in a–d are from separate experiments. Data represent the mean (±SD) of five experi-
ments (b). Data are from one of three independent experiments (c and d). IL-17-TH2, IL-17–producing TH2 cells.
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mAbs can block the up-regulation of select chemokine 
genes induced by treatment with supernatant from IL-17– 
producing TH2 cells (Fig. 4 b). These results suggest that the 
IL-17 and TH2 cytokines produced concurrently by IL-17– 
producing TH2 cells can selectively enhance the expression of 
pro-allergic chemokine genes in lung epithelial cells, particu-
larly eotaxin-3.
Increased frequency of IL-17–producing TH2 cells  
in patients with atopic asthma
Previous studies have showed that CRTH2+CD4+ TH2 
cells circulate in the peripheral blood of all healthy sub-
jects tested, ranging from 2–4% of total CD4+ T cells, and 
that the frequency of these cells is elevated in patients with 
atopic dermatitis (Cosmi et al., 2000). To examine whether 
an increased frequency of circulating IL-17–producing TH2 
cells is associated with patients with atopic asthma, 39 sub-
jects were recruited for the study (23 subjects with atopic 
asthma and 16 healthy control subjects). Subject charac-
teristics are summarized in Table I. The number of total 
CD4+CRTH2+ TH2 memory/effector cells and of CCR6+ 
and CCR6 of CD4+CRTH2+ TH2 cell subset cells from 
the peripheral blood of subjects were analyzed and com-
pared by flow cytometry. Consistent with a previous study 
(Cosmi et al., 2000), the number of circulating total 
CD4+CRTH2+ TH2 memory/effector cells in subjects with 
the airway of atopic patients (Kolls et al., 2003). To address 
whether the combination of IL-17 and TH2 cytokines can 
synergistically induce chemokine production, which would 
enhance the recruitment of inflammatory cells, we treated 
normal human bronchial epithelial cells or bronchial epithe-
lial cell lines (BEAS-2) with various combinations of IL-17 
and TH2 cytokines. Compared with the treatments of IL-13, 
TNF, IL-17, IL-13 with TNF, or IL-17 with TNF, the com-
bination of IL-17, TH2 cytokines, and TNF induced the 
greatest increase in gene expression of eotaxin-3 (>500-fold), 
IL-8 (>200-fold), MIP-1 (>40-fold), and Gro- (>15-fold), 
but not MCP-1 or eotaxin-1, in the normal human bronchial 
epithelial cells and bronchial epithelial cell lines (BEAS-2; 
Fig. 4 a and not depicted). In a parallel experiment, we ex-
amined the effect of supernatants collected from activated 
IL-17–producing CD4+CCR6+CRTH2+ TH2, classical 
CD4+CCR6CRTH2+ TH2, or CD4+CCR6+CRTH2 
TH17 cells on the induction of chemokine gene expression in 
normal human bronchial epithelial cells. Compared with the 
supernatants collected from activated classical TH2 or TH17 
cells, we found that the cytokine milieu secreted by IL-17–
producing TH2 cells was the most effective in inducing the 
up-regulation of eotaxin-3 (>1,000-fold), IL-8 (>30-fold), 
Gro- (>12-fold), MCP-1 (>20-fold), and MIP-1 (10-
fold), but not eotaxin-1 gene expression in normal bronchial 
epithelial cells (Fig. 4 b). Notably, neutralizing anti–IL-17 
Figure 2. The novel human CCR6+CRTH2+CD4+ TH2 cell subset displays features of both TH2 and TH17 cell lineages. Sorted CCR6+ (b-e) and 
CCR6 (f) subsets of CRTH2+CD4+ TH2 and CCR6+CRTH2CD4+ TH17 (g) cells were cultured in the homeostatic cytokines IL-7/IL-15 in the presence of 
anti–IL-4 and anti–IFN- mAbs for 3 d. Expanded cells were collected and restimulated with PMA plus ionomycin for analysis of intracellular cytokine 
production (a) or activated with anti-CD3 before two-color immunofluorescent staining with anti–human RORt (red) or GATA-3 (green) mAb (b-g). Cell 
nuclei were identified with DAPI (blue). Numbers within the quadrants indicate the percentage of cultured cells that stained positive for each respective 
cytokine. Bars, 5 µm. Data are from one of three independent experiments (a–g). IL-17-TH2, IL-17–producing TH2 cells.
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suggest that patients with atopic asthma may have increased 
frequency of inflammatory IL-17–producing TH2 cells in 
their blood.
IL-17–producing TH2 cells are induced in inflamed  
lung in vivo
To further establish the function of IL-17–producing TH2 cells 
in the pathogenesis of asthma in vivo, we used a previously de-
scribed mouse model of allergic lung diseases by challenging 
IL-4-eGFP knock-in (4GET) mice six times intranasally with 
Aspergillus oryzae or papain (Henderson et al., 1996). 1 d after the 
last challenge, CD4+CD62LCD44hi memory/effector T cells 
isolated from lung or other lymphoid tissues were stimulated 
with PMA and ionomycin for intracellular cytokine analyses. As 
shown in Fig. 6 a, two populations of the infiltrating CD4+ cells 
atopic asthma was significantly higher than that of healthy 
controls (8.05 ± 2.58 × 104 [n = 23] vs. 3.22 ± 0.76 × 104 
[n = 16], mean ± SD; Fig. 5 a). Notably, the number of 
circulating CCR6+CD4+CRTH2+ IL-17–producing TH2 
cells in subjects with atopic asthma is 5.8-fold higher than 
that found in the healthy donors (2.84 ± 1.33 vs. 0.49 ± 
0.19 × 104, mean ± SD), whereas the number of classical 
CCR6CD4+CRTH2+ TH2 cells is 1.9-fold higher than 
that in the healthy donors (5.19 ± 2.73 vs. 2.73 ± 0.71 × 104, 
mean ± SD; Fig. 5 b). Purified CCR6+CD4+CRTH2+  
TH2 cells obtained from asthma patients (n = 9) produced 
large amounts of inflammatory cytokines, IL-17, IL-22, and 
TNF, together with classical TH2 cytokines; in contrast, iso-
lated CCR6CD4+CRTH2+ TH2 cells produced only TH2 
cytokines and a lesser amount of TNF (Fig. 5 c). These results 
Figure 3. Proinflammatory stimuli induce classical CD4+ TH2 cells to produce IL-17 cytokine. Sorted CCR6CRTH2+CD4+ TH2 cells were main-
tained with homeostatic cytokines IL-7/IL-15 plus anti–IL-4 and anti–IFN- mAbs in the presence or absence of the indicated proinflammatory cytokines 
for 6 d. Expanded cells were restimulated with PMA plus ionomycin for the analysis of intracellular cytokine production (a) or anti-CD3/CD28 for mea-
surement of cytokines in the culture supernatants by ELISA (b) or were used as cDNA templates for the indicated gene expression analysis by real-time 
PCR (c). Fold differences in gene expression level between cell/treatment groups marked in the horizontal axis are indicated in the left panel. Data repre-
sent the mean (±SD) of five experiments (b). Data are from one of three independent experiments (a and c).
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inflamed lung, but not other lymphoid organs, 
produced large amounts of IL-17A, IL-17F, 
IL-22, IL-21, and IFN-, but very little of IL-4, 
IL-5, and IL-13, indicative of the classical TH17 
or TH1 cell subsets (Fig. 6 b). These data suggest 
that the IL-17/IL-4–double- producing TH2 cells 
were induced selectively in inflamed lung, but 
not in the draining lymph nodes or other lym-
phoid tissues in this mouse model of asthma.
IL-17–producing TH2 cells are increased in inflamed lung 
during chronic phase
Allergen-specific TH2 memory cells that reside in lung during 
disease remission are the principle cell type responsible for the 
exacerbation of allergic asthma (Epstein, 2006). To characterize 
lung-resident memory T cells after remission, we analyzed intra-
cellular cytokine production by CD4+CD62L memory/ 
effector T cells in the lung and other lymphoid tissues from mice 
that rested for different periods of time after the last allergen 
challenge. 3 h after the last challenge, the majority of lung 
CD4+CD62L memory/effector T cells were found to be the 
conventional IL-17+IL-4(GFP) TH17 cells (20%) or the 
classical IL-17–IL-4+(GFP+) TH2 cells (16%); only 3% of lung 
memory/effector CD4+ T cells were IL-17–producing TH2 cells 
(IL-17+GFP+; Fig. 7 a). Notably, the frequency of conventional 
TH17 cells that reside in the lung declined rapidly to 10% 1 d 
after the last challenge. Conversely, the frequency of the IL-17–
producing TH2 cells accumulated to 20% of total lung resident 
CD4+CD62L memory/effector T cells in mice that rested for 
in the lung of mice challenged with either allergen Aspergillus 
oryzae or papain expressed either IL-4 (GFP+; 36%) or IL-17 
(10%), indicative of the conventional TH2 and TH17 cells, 
respectively. Notably, a third population (4%) in inflamed 
lung produced both IL-4 (GFP+) and IL-17 cytokines (Fig. 6 a). 
Very few IL-4/IL-17–double-producing T cells were detected 
in the lung draining lymph nodes, spleen, or intestine mesen-
teric lymph nodes, although a significant number of conven-
tional IL-4+ (GFP+)/IL-17– TH2 or TH17 cells could be observed 
in these lymphoid organs (Fig. 6 a). ELISA analyses further 
showed that GFP+CD4+ TH2 cells isolated from inflamed lung 
concomitantly produced the classical TH2 cytokines IL-4, IL-5, 
and IL-13 and the inflammatory TH17 cytokines IL-17A, 
IL-17F, and IL-22 after restimulation with anti-CD3/CD28 
mAbs for 24 h (Fig. 6 b). In contrast, GFP+CD4+ TH2 T cells 
isolated from spleen, lung draining lymph nodes, or intestine 
mesenteric lymph nodes could produce moderate levels of TH2 
cytokines, but very low levels of IL-17A, IL-17F, and IL-22 
(Fig. 6 b). In addition, GFPCD4+ non-TH2 cells isolated from 
Figure 4. Combinations of IL-17 and TH2 cyto-
kines induce profound up-regulation of chemokine 
gene expression. cDNA templates made from cultured 
normal human bronchial epithelial cells treated with or 
without the indicated cytokines (a) or supernatants 
collected from indicated T helper subsets activated by 
anti-CD3/CD28 mAbs for 24 h in the presence or ab-
sence of anti–IL-17 neutralizing antibodies (b). Expres-
sion levels of indicated chemokine genes were 
measured by real-time PCR as described in the Materi-
als and methods. Fold differences in gene expression 
level between treatment groups marked in the horizon-
tal axis are indicated in the left panel. Data are from 
one of three independent experiments (a and b). IL-17-
TH2, IL-17–producing TH2 cells.
Table I. Characteristics of the study population
Charactristics Atopic asthma subjects Healthy control subjects
n = 23 n = 16
Age, yr 50 (27–65) 34 (24–46)
Sex (male/female) 9/14 10/7
Onset of asthma (childhood/adulthood) 8/17 –
FEV1, percentage predicted 68 (31–98) 107 (102–121)
Percentage of PEF variability 20 (12–69) ND
Skin test positive 23 (100%) ND
Data are presented as median with interquartile ranges. FEV1, forced expiratory volume in the first second; PEF, peak expiratory flow; ND, not done.
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OVA peptides in the presence of IL-1, IL-6, IL-23, and 
anti–IFN- or IL-4 and anti-IFN-, respectively. OVA-specific 
TH17 cells were generated by co-culturing splenic CD4+  
T cells from naive DO11.10X4GET mice with APC pulsed 
with OVA peptides in TH17-polarizing conditions. BALB/c 
mice were transferred intravenously with a single OVA-specific, 
IL-17–producing TH2, classical TH2, or TH17 cell subset, with 
both the classical TH2 and TH17 cell subsets, or with saline 
only; mice were then challenged with OVA intranasally once 
a day for 2 d. As shown in Fig. 8 a, bronchoalveolar lavage 
fluid (BALF) from mice transferred with OVA-specific, IL-17–
producing TH2 cells or both the classical TH2 and TH17 cell 
subsets contained about threefold more infiltrating cells than 
those from mice transferred with only OVA-specific classical 
TH2 or TH17 cells or saline alone. Moreover, we found that 
mice transferred with OVA-specific IL-17–producing TH2 cells 
or both the classical TH2 and TH17 cell subsets exhibited 
markedly enhanced recruitments of eosinophils, neutrophils, 
macrophage, and lymphocytes into the airway, whereas mice 
transferred with only OVA-specific classical TH2 or TH17 
cells showed a moderate influx of eosinophils or neutrophils 
and macrophages into the airway, respectively, after intra-
nasal OVA challenges (Fig. 8 b). Interestingly, a significant 
increase of inflammatory cytokines, IL-1 and IL-6, and a 
moderate increase of IL-5 and IL-13, but not IFN- produc-
tion, were detected in the BALF of mice transferred with 
OVA-specific, IL-17–producing TH2 cells or both the classical 
TH2 and TH17 cell subsets compared with those in BALF of 
mice transferred with OVA-specific classical TH2 or TH17 cells 
or saline only (Fig. 8 c). Histological analyses of lungs from 
mice transferred with OVA-specific, IL-17–producing TH2 cells 
or both the classical TH2 and TH17 cell subsets exhibited 
markedly enhanced peribronchial inflammation with infil-
trated eosinophils and neutrophils, more prominent mucin 
production, and goblet cell hyperplasia compared with lungs 
from mice transferred with conventional TH2 or TH17 cells 
or saline only (Fig. 8 d). These results suggest that during the 
allergen recall response, antigen-specific IL-17–producing TH2 
cells may have additional inflammatory properties, similar to 
those of the combined TH2 and TH17 cells, which promote 
the infiltration of heterogeneous leukocytes and exacerbate 
the immunopathology of allergic asthma.
DISCUSSION
Severe asthma is a heterogeneous disorder with distinct types 
of inflammatory processes. Although the discovery of IL-17–
producing T cells has shed light on the understanding of the 
underlying mechanisms that contribute to the heterogeneity 
and severity of asthma, the identity of IL-17–producing T cells 
in allergic diseases, including asthma remain elusive. In this 
study, we identified a distinct population of human IL-17–
producing TH2 cells characterized by (a) the capability of 
concomitantly producing the classical TH2 cytokines IL-4, 
IL-5, and IL-13, and the inflammatory TH17 cytokines IL-17 
and IL-22; (b) dual expression of the TH17-transcription 
factor RORt and the TH2-transcription factor GATA3; and 
6 d, and this increase was maintained for at least 12 d after the 
last challenge (Fig. 7, a and b). In addition, IL-17–producing 
TH2 cells could be found in the lung draining lymph nodes 
(>5%) and spleen (>1.3%), but not in the mesenteric lymph 
nodes 6 d after the last challenge, suggesting that some of IL-17–
producing TH2 cells migrate out of the inflammatory sites into 
the periphery (Fig. 7, a and b). These results suggest that upon 
exposure to allergens, the influx of TH17 cells into inflammatory 
lung can occur rapidly within 3 h, but that the IL-17–producing 
TH2 cells persist in lung and may be the dominant IL-17– 
producing T cells during the chronic phase of inflammation.
IL-17–producing TH2 cells exacerbate allergic inflammation
Because the expression level of IL-17 is associated with the 
severity of asthma in patients (Molet et al., 2001; Chakir et al., 
2003), we assessed the relative roles of the classical TH17, 
classical TH2, and IL-17–producing TH2 cells in the patho-
genesis of allergic asthma. To generate OVA-specific IL-17–
producing TH2 or classical TH2 cells, splenic CD4+ TH2 cells 
were first isolated from OVA/alum adjuvant–sensitized 
4GET mice carrying OVA-specific DO11.10 TCR trans-
gene (DO11.10X4GET). OVA-specific IL-17–producing 
TH2, or classical TH2 cells, were then further induced by co-
culturing splenic CD4+ TH2 cells with APCs pulsed with 
Figure 5. An increased number of circulating IL-17–producing  
TH2 cells is associated with patients with allergic asthma. Total CD4+ 
T cells from peripheral blood of healthy donors (n = 16) or subjects with 
allergic asthma (n = 23) were enriched and counted by hemacytometer. 
Cell numbers of total CRTH2+CD4+ TH2 cells (a) and of CCR6+ and CCR6 
subsets of CRTH2+CD4+ TH2 cells (b) were obtained based on their the 
percentage within enriched CD4+ T cells by multicolor immunofluores-
cence analyses. (c) Sorted CCR6+ or CCR6 subsets of CRTH2+CD4+  
TH2 cells from subjects with atopic asthma (n = 9) were restimulated with 
anti-CD3/CD28 mAbs for 24 h before measurement of the secreted cyto-
kines in the supernatants by ELISA.
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Figure 6. The induction of IL-17–producing TH2 cells occurred in the inflamed lung after allergen exposure. 4GET mice (n = 4) were challenged 
with indicated allergens plus OVA intranasally every other day for a total of six times before sacrifice. Sorted total (a) or GFP+ and GFP subsets (b) of 
CD4+CD62LCD44hi memory/effector T cells from lung or indicated lymphoid tissues were restimulated with PMA plus ionomycin for the analysis of in-
tracellular cytokine production (a) or with anti-CD3/CD28 mAbs for 24 h before measurement of cytokines in the supernatants by ELISA (b). Data are from 
one of three independent experiments (a and b). Data represented as the mean (±SD); four mice per group. LLN, lung draining LNs; MLN, intestine mesen-
teric LNs.
Figure 7. Inflammatory IL-17–producing 
TH2 cells persist in the inflamed lung dur-
ing the chronic phase of allergic asthma. 
4GET mice (n = 4) were challenged with As-
pergillus Orazae plus OVA intranasally every 
other day for a total of six times (a and b). 
After the last challenge, mice rested for the 
indicated time frame (a and b; horizontal axis) 
before sacrifice. Purified CD4+CD62LCD44hi 
memory/effector T cells from lung or other 
lymphoid tissues were restimulated with PMA 
plus ionomycin for the analysis of intracel-
lular cytokine production (a). The percentage 
of indicated cytokine producing cells within 
the total CD4+ memory/effector T cell pool 
were numerated as shown on the left axis (b). 
Data are representative of two independent 
experiments. Data represented as the mean 
(±SD); four mice per group.
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that the TGF-, IL-21, or IL-23, as well as the proinflamma-
tory cytokines IL-1 or IL-6, are important for the induction 
of IL-17 cytokine production (Mangan et al., 2006; Veldhoen 
et al., 2006; Wilson et al., 2007; Manel et al., 2008; Volpe 
et al., 2008; Yang et al., 2008). However, recent findings 
suggest that some cytokines, such as IL-1 (Tillie-Leblond 
et al., 1999; Nakae et al., 2003; Chung et al., 2009) and IL-21 
(Fröhlich et al., 2007; Nurieva et al., 2007; Leonard et al., 
2008; Yang et al., 2008), and the transcription factor IRF4 
(Rengarajan et al., 2002; Brüstle et al., 2007; Honma et al., 
2008) are important for the development of both TH2 and 
TH17 immune responses, suggesting that the plasticity between 
the development and maintenance of TH2 and TH17 cells 
may exist. Our finding of the novel subset of CD4+ TH2 
memory/effector cells capable of producing IL-17 supports 
this hypothesis. Notably, we showed that the proinflamma-
tory cytokine IL-1, IL-6, and IL-21 could directly induce 
the up-regulation of IRF4 and RORt gene expression and 
the production of IL-17 in classical TH2 memory/effector 
cells in vitro. At the early phase of allergic inflammation in an 
(c) surface expression of CD45RO, the chemokine receptors 
CCR4 and CXCR4, and CLA, suggesting a memory pheno-
type and readiness to migrate into inflammatory mucosa sites. 
Notably, the number of circulating IL-17–producing TH2 
cells is significantly increased in patients with atopic asthma. 
Moreover, we demonstrated that the mouse counterpart of 
IL-17–producing CD4+ TH2 cells are selectively induced in 
the inflamed lung and are the dominant IL-17–producing 
T cells during the chronic phase of asthma in vivo. Mice trans-
ferred with antigen-specific, IL-17–producing TH2 cells ex-
hibited profound immunopathological allergic inflammation 
after recall response. These data suggest that the IL-17– 
producing CD4+ TH2 cells may represent the inflammatory 
TH2 cells that promote the pathophysiology of asthma.
The TH17 cell lineage possesses a unique genetic program 
and is described as an additional branch of the T helper cell 
subsets (Harrington et al., 2005; Park et al., 2005b; Ivanov 
et al., 2006). Studies in vitro demonstrated that the absence of 
TH2 and TH1 cytokines is the prerequisite for TH17 cell dif-
ferentiation from naive T cells (Veldhoen et al., 2006) and 
Figure 8. Antigen-specific inflammatory IL-17–producing TH2 cells promote the exacerbation of allergic asthma. Five groups of BALB/c mice 
were intranasally challenged once a day for 2 d with OVA 24 h after being adoptive transferred with 0.9% saline as a control or OVA-specific IL-17– 
producing TH2, classical TH2, classical TH17, or classical TH2 and TH17 cells generated in vitro, as described in Materials and methods. BALF of individual 
mice of each group were collected for the measurement of total cell counts (a) and differential cell counts (b), indicating that the total numbers of indi-
vidual inflammatory cells in each group or (c) concentrations of indicated cytokines by ELISA. (d) Histological analysis of representative lung bronchovas-
cular bundles stained with hematoxylin and eosin (H&E; top) or stained with periodic acid Schiff (PAS; bottom). The insets at the corner depict higher 
magnification images of the airway epithelium stained with PAS, showing that much more abundant mucus-producing cells (pink cytoplasm) are lining 
the airway epithelium of mice receiving indicated T helper cell subsets. Data are representative of three independent experiments. Data represented as the 
mean (±SD); four mice per group. Bars: (capped) 100 µm; (uncapped) 10 µm.
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including neutrophils, eosinophils, macrophage, and lym-
phocytes, which resulted in profound goblet hyperplasia as 
well as elevated mucin production after antigen sensitization. 
In contrast, mice transferred with conventional TH2 or TH17 
cells exhibited fewer airway infiltrations of eosinophils or 
neutrophils, respectively, and limited pathophysiological fea-
tures. The finding that the frequency of circulated IL-17–
producing TH2 cells is significantly elevated in atopic asthma 
patients further highlights the potential role of this novel cell 
subset in the exacerbation of allergic diseases. Future analyses 
on the frequency and characteristics of the inflammatory IL-17–
producing TH2 cells in patients with different subtypes of 
asthma may facilitate the understanding of the heterogeneity 
and severity of allergic asthma.
Patients with severe allergic asthma during remission often 
have elevated nitric oxide breath levels that are indicative of 
their persistent lung inflammation and are possibly mediated 
by resident allergen-specific TH2 memory cells (Yurovsky et al., 
1998; Bates and Silkoff, 2003). The identification of the 
TH17 cell lineage and its confounding roles in the pathogen-
esis of allergic inflammation have has further unveiled the 
complexity of atopy (Nakae et al., 2002; Schnyder-Candrian 
et al., 2006) and raises new questions on how TH17 cells and 
TH2 cells cooperate to mediate the severity and heterogene-
ity of allergic asthma. The temporal recruitments and inter-
play between these two T helper subsets have been suggested 
as the cause of the heterogeneity in the pathology of severe 
asthma (Larché et al., 2003; Schmidt-Weber et al., 2007). 
In an animal model of asthma, we showed that the influx of 
TH17 cells could occur within the first 3 h after the last chal-
lenge; however, the majority of IL-17–producing T cells 
persisted in the lung from day 3 after the last challenge and 
were found to express low-to-high levels of GFP (IL-4) that 
were indicative of their TH2 characteristics. Our findings 
suggest that the rapid influx of TH17 cells may be part of the 
inflammatory processes triggered by the injured epithelial 
cells or altered innate immunity induced by environmental 
stimuli or invaded pathogens at the acute phase of allergic 
asthma. Antigen-specific classical TH2 or IL-17–producing 
TH2 cells that respond to allergen sensitization may reside 
in the lung and contribute to the persistence and progression 
of chronic allergic asthma. Designing curative therapy for 
chronic allergic diseases in a phase-specific manner may re-
quire not only the understanding of the factors that regulate 
the balance for the development of various T helper subsets, 
but also their temporal sequences and potential interactions 
in the induction of immunopathology of allergic asthma.
MATERIALS AND METHODS
Cell culture and isolation of human TH2 and TH17 memory cell 
subsets. This study was approved by the institutional review board for human 
research at The University of Texas M.D. Anderson Cancer Center (Houston, 
Texas). Human CD4+ TH2 memory/effector T cells were enriched by 
the depletion of other lineage cells using microbeads and then sorted as 
CD4+CRTH2+CCR6+Lineage or CD4+CRTH2+CCR6Lineage cells. 
TH17 cells were sorted as CD4+CRTH2CCR6+ Lineage cells with purity 
>99%, as previously described (Wang et al., 2006). In some experiments, 
animal model of allergic lung diseases, IL-17–producing TH2 
cells could primarily be found in the inflamed lung along 
with other T helper subsets, including classical TH2 and TH17 
cells, and some TH1 cells. Notably, these resident IL-17– 
producing TH2 cells persist in inflamed lung as the dominant 
IL-17–producing T cells at the chronic stage of airway aller-
gic inflammation. Collectively, these observations suggest 
that substantial plasticity exists within CD4+ TH2 memory/
effector cells and that this plasticity may be controlled by 
local inflammatory cues. In theory, naive CD4+ T cells or 
TH17 cells may also have the potential to become IL-4/IL-17– 
dual-producing cells. It is possible that some naive T cells 
may not have to undergo the TH2 or TH17 differentiation 
pathway and may become IL-4/IL-17 double producers 
through subsequent regulation from unique microenviron-
ments in vivo. Recent studies have reported that TH17 cells 
have the plasticity to become other cell lineages (Lee et al., 
2009; Zhu and Paul, 2010). To test whether TH2-polarizing 
signals could induce TH17 cells to become IL-4/IL-17 dou-
ble producers, in our pilot studies, we found that TH2- 
polarizing stimuli (thymic stroma lymphopoietin–activated 
DCs or IL-4) could induce the freshly isolated human 
CCR6+CRTH2 TH17 cells to produce IL-4, but shut down 
their IL-17 production in vitro (unpublished data). However, 
during the revision of this study, findings from the character-
izations of human CD4 T cell clones point to the possibility 
that TH17 cells may have the potential to become IL-4/IL-17 
dual-producing cells (Cosmi et al., 2010). Understanding the 
cellular origin and the underlying mechanisms that drive the 
induction of IL-4/IL-17 double producers during allergic in-
flammation is the basis for further investigations.
The severity of asthma is correlated with the level of 
IL-17 cytokine found in the lung, sputum, BALF, or serum 
of patients (Molet et al., 2001; Chakir et al., 2003). One of 
the major functions of the cytokine IL-17 during asthmatic 
reactions is to orchestrate the sustained neutrophilic mobili-
zation (Kolls et al., 2003; Lindén et al., 2005). However, the 
mixed eosinophilic, neutrophilic, and granulocytic infiltra-
tions with greatly increased total cell number are often ob-
served in the sputum of patients in some subtypes of severe 
allergic asthma (Simpson et al., 2006), and the underlying 
cellular and molecular mechanisms remain unknown. One of 
the mechanisms involved in the IL-13–mediated pathophysi-
ological features of asthma is the induction of chemokine 
production by airway structural cells (Zimmermann et al., 
2003). We found that the combination of inflammatory 
IL-17 and TH2 cytokines IL-4 and IL-13 or the use of a cyto-
kine milieu produced by IL-17–producing TH2 cells have 
profound synergistic effects on the induction of various che-
mokine genes in primary lung bronchial epithelial cells, such 
as MIP-1, MCP-1, Gro-, IL-8, and eotaxin-3, which is par-
ticularly effected. The effects of IL-17–producing TH2 cells 
on promoting the recruitments of inflammatory leukocytes 
were further substantiated in this animal model of asthma in 
vivo. Transfer of antigen-specific, IL-17–producing TH2 cells 
triggered much stronger influx of heterogeneous leukocytes, 
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Purified T cells were analyzed for cytokine production by intracellular 
cytokine staining or ELISA as described above.
Generation of OVA-specific TH subsets. For the generation of OVA-
specific TH17 cells, CD4+ T cells were obtained from splenocytes of naive 
DO11.10 × 4GET mice, enriched by magnetic anti-CD4 microbeads, and 
then cultured with irradiated CD4 spleen cells pulsed with OVA 323–339 
peptide in the presence of 5 ng/ml TGF- (Peprotech), 20 ng/ml IL-6 
(Peprotech), 10 µg/ml IL-23 (R&D systems), 20 µg/ml anti–IL-4 mAb (BD), 
and 20 µg/ml anti–IFN- mAb (BD). For the generation of OVA-specific 
TH2 subsets, DO11.10X4GET mice were first immunized intraperitoneally 
with 100 µg of OVA in 2 mg of aluminum hydroxide (Thermo Fisher Sci-
entific). OVA-specific IL-17–producing TH2 cells or conventional TH2 cells 
were then generated from enriched CD4+ T cells cultured with irradiated 
CD4 spleen cells pulsed with OVA323-339 peptide in the presence of 
20 ng/ml IL-1 (R&D systems), 20 ng/ml IL-6, and 10 µg/ml IL-23 plus 
20 µg/ml anti–IFN- mAbs or 10 ng/ml IL-4 (Peprotech) and 20 µg/ml 
anti-IFN- mAb, respectively.
Adoptive transfer experiments for antigen-induced airway inflam-
mation. The IL-17–producing TH2 cells, conventional TH2 cells, or TH17 
cells were transferred intravenously into BALB/c mice (2 × 106 cells/mouse). 
Control mice received saline intravenously. 1 d after transfer, mice were in-
tranasally challenged with OVA (50 µg/ml) every day for a total of two 
times. Mice were sacrificed 24 h after the last challenge. Total cell numbers 
or numbers of eosinophils, neutrophils, macrophage, and lymphocytes in the 
BALF were numerated, and the levels of IL-1, IL-6, IL-5, IL-13, and 
IFN- in the BALF were evaluated by ELISA. For the histological analyses, 
individual lung were fixed in 10% buffer formalin. Hematoxylin and eosin, 
Giemsa, and periodic-acid Shiff staining were performed by Histology Con-
sultation Services, Inc.
Subjects and study design. Study participants were recruited from pa-
tients diagnosed in the Bernstein Allergy Group, and the Clinical Research 
Center in the Division of Allergy and Immunology at the University of 
Cincinnati. The study was approved by the University of Cincinnati Institu-
tional Review Board. Patients taking any oral topical skin medication were 
excluded from the study. Exclusion criteria include: (a) having had an acute 
viral infection within at least 1 mo before the study; (b) being a smoker or 
ex-smoker who has had ≥10 pack per year smoking history; (c) having any 
unstable chronic disease (other than asthma), or (d) being pregnant. Inclusion 
criteria were as follows: (a) age 18–65 yr; (b) history of allergic asthma lasting 
for 1 yr or longer based on previous diagnosis in our clinics; (c) positive skin 
prick tests (wheal diameter >5 mm) to one or more of the following aller-
gens: timothy grass pollen, ragweed, cockroach, mold, house dust mite, or 
cat dander in the presence of positive histamine and negative vehicle control; 
(d) receiving inhaled corticosteroids with or without other medications for 
asthma, including 2-agonists, leukotriene modifying agents or sustained re-
lease theophylline for at least 2 mo. All asthmatic subjects must have a ≥12% 
improvement in forced expiratory volume in the first second of exhalation 
(FEV1) or a fall of >20% or more in response to a provocative methacholine 
dose ≤10mg/ml, confirming airway hyperresponsiveness. All subjects under-
went a thorough history (including an asthma control test), physical exami-
nation, weight to determine body mass index, and allergy skin prick testing. 
Atopy is defined by one or more positive skin prick tests to at least one com-
mon inhalant allergen.
Statistical analysis. Data were analyzed using GraphPad Prism 5 software. 
Data are presented as mean value ± SD and analyzed using Student’s t test 
(n = 2 groups). P values of <0.05 were considered significant.
We thank Dr. Marc E. Rothenberg for critically reading the manuscript and 
discussions; Dr. Dan Littman for providing anti–human RORt mAb; Dr. David 
Corry for suggestions; Karen Ramirez and Zhiwei He for cell sorting assistance; and 
Shawna Hottinger for editorial assistance.
purified CD4+CRTH2+CCR6 TH2 cells were cultured with 20 ng/ml 
IL-7 and 10 ng/ml IL-15 plus 2 µg/ml anti–IL-4 and 1 µg/ml anti–IFN-  
mAbs (R&D Systems) in the presence or absence of 10 ng/ml IL-1, 
25 ng/ml IL-6, 10 ng/ml IL-21, or 25 ng/ml IL-23 (R&D Systems), or in 
the combination of these cytokines for the induction of IL-17 production. 
Human primary normal bronchial epithelial cells (Lonza) were maintained 
in bronchial epithelial growth medium (Lonza), and the bronchial epithelial 
cell line (BEAS-2) was cultured following the instructions of American Type 
Culture Collection.
Analysis of cytokine production. Freshly isolated or expanded human 
TH2 cell subsets or TH17 cells were stimulated with immobilized anti-CD3 
(OKT3; 5 µg/ml) and soluble anti-CD28 (L293.1; 1 µg/ml) for 24 h. Col-
lected supernatants were assessed by ELISA for IL-4, IL-5, IL-13, IL-17, 
IL-22, IFN-, IL-10, and TNF production (R&D Systems). In mouse 
experiments, sorted GFP+ or GFP CD4+CD62L memory/effector T cells, 
isolated from 4GET mice challenged intranasally with the allergen Aspergillus 
oryzae 6 times were stimulated with immobilized 5 µg/ml anti-CD3 and sol-
uble 1 µg/ml anti-CD28 for 24 h. Collected supernatants were assessed by 
ELISA for IL-4, IL-5, IL-13, IL-17A, IL-17F, IFN-, IL-10, TNF (R&D 
Systems), and IL-22 production (Antigenic American). Intracellular cytokine 
analyses were performed using PE-IL-4, FITC-IFN- (BD), and APC-IL-17 
(eBioscience) in human studies and PE-IL-17 (eBioscience) and APC-IFN- 
(BD) in mouse experiments.
RNA isolation and real-time quantitative PCR. Total RNA samples 
from sorted or cultured cells were isolated by RNeasy kit (QIAGEN). The 
cDNA templates were synthesized using SuperScript II (Life Technologies). 
Oligonucleotide primers were selected using Primer Express 2.0 (Applied 
Biosystems). Real-time quantitative PCR was performed with the ABI Prism 
7900 (Applied Biosystems) detection system. For the analysis of GATA3, 
c-maf, T-bet, NFATc1, IL-4, and IL-5 gene expression, real-time PCR probes 
were purchased directly from the manufacturer (Applied Biosystems). For 
analyses of chemokine gene expression, transcripts were amplified using an 
annealing temperature of 60°C and the following primers: CXCL1/Gro-; 
5-AGGGAATTCACCCCAAGAACAT-3 and 5-GATGCAGGATTG-
AGGCAAGCT-3; CXCL-8, 5-CTCTTGGCAGCCTTCCTGATT-3  
and 5-TATGCACTGACATCTAAGTTCTTTAGCA-3; Eotaxin-3, 
5-CTGGGTGCGAAGCTATGAAT-3 and 5-TCTTGCCTCTTTTGG-
TAGTGAA-3; and CCL-3/MIP-, 5-CACCTCCCGGCAGATTCC-3 
and 5-GCCGGCTTCGCTTGGTTA-3. For each sample, mRNA abun-
dance was normalized to the amount of 18S rRNA or GAPDH and ex-
pressed as arbitrary units, as described previously (Wang et al., 2006).
Immunohistology. For immunofluorescent staining, cultured human 
T helper subsets were activated by anti-CD3 for 6 h before being cytospun 
onto the slides. The tested slides were fixed and incubated with goat anti-
GATA3 (Santa Cruz Biotechnology, Inc.) and mouse anti–human RORt 
mAb (provided by D. Littman, Skirball Institute of Biomolecular Medicine, 
New York University School of Medicine, New York, NY) at room tem-
perature for 1 h, followed by Alexa Fluor 488-F(ab’)2 fragment rabbit anti–
goat IgG antibody (Invitrogen). After washing and blocking, cells were 
counterstained with biotinylated horse anti–mouse antibodies and visualized 
by Alexa Fluor 549–conjugated streptavidin (Invitrogen).
Induction and analysis of a mouse model of allergic lung diseases. 
We used a previously well-established animal model of allergen-induced air-
way disease (Henderson et al., 1996). In brief, 4GET or DO10.11X4GET 
mice were anesthetized with isoflurane and subjected to intranasal inhalation 
of 50 µl of OVA only, Aspergillus oryzae with OVA, or Papain with OVA 
every other day for a total of 6 challenges. Potential endotoxin contamina-
tion was removed from OVA by endotoxin-removing gel (Thermo Fisher 
Scientific). After the last challenge, mice were sacrificed at various time 
points and CD4+CD62L memory/effector T cells were sorted from the 
lung, spleen, lung draining lymph nodes, and mesenteric lymph nodes. 
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